Anbio Biotechnology
NNNN- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001982708
No open-market purchases or sales by Anbio Biotechnology insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $985.2K in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding Anbio Biotechnology changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 5 | 8 | +3 |
| Shares | 29.7K | 50.2K | +20.5K (+68.9%) |
| Value | $894.3K | $1.29M | +$396.0K (+44.3%) |
New holders (3)
Institutions that held Anbio Biotechnology at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| EverSource Wealth Advisors, LLC | 266 | $6.83K | 0.00% |
| Bare Financial Services, Inc | 15 | $385 | 0.00% |
| Ronald Blue Trust, Inc. | 5 | $128 | 0.00% |
Sold out (0)
Institutions that held Anbio Biotechnology at the end of Q4 2025 and filed for Q1 2026 without it.
None.